Jun 01, 2020
Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
May 29, 2020
Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
Apr 29, 2020
Sumitovant Biopharma Announces Publication of Myovant Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 Liberty Studies in Uterine Fibroids in Obstetrics & Gynecology
Mar 05, 2019
Myovant Sciences to Present at Upcoming Investor Conferences
Feb 07, 2019
Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018
Dec 20, 2018
Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
Oct 24, 2018
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
Oct 10, 2018
Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress
Oct 08, 2018
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
Aug 28, 2018
Myovant Sciences to Participate in Two Upcoming Investor Conferences
Aug 07, 2018
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
Jul 12, 2018
Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares
Jul 11, 2018
Myovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares
Jul 10, 2018
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
Jun 18, 2018
Myovant Sciences to Present at First Annual Roivant Pipeline Day
Jun 07, 2018
Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018
Mar 06, 2018
Myovant Sciences to Present at Upcoming Investor Conferences
Feb 13, 2018
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
Jan 04, 2018
Myovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Nov 21, 2017
Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference